Exhibit 99.2
NOTICE OF ANNUAL
GENERAL MEETING OF
IMMATICS N.V.
Notice is given that the annual general meeting
of Immatics N.V., a public company under Dutch law, registered with the Dutch trade register under number 77595726 (the "Company"),
will be held at the offices of CMS Netherlands, Atrium, Parnassusweg 737, 1077 DG Amsterdam, the Netherlands, on 17 June 2021 at 14.00
hours CET (the "AGM").
Agenda
The agenda for the AGM and related documents
and further information regarding the AGM can be found on the Company's website at https://investors.immatics.com/events/event-details/annual-general-meeting-0.
They are also available for inspection and can be obtained free of charge at the offices of the Company.
COVID-19 pandemic
Taking into account the current status of the
pandemic and applicable restrictive measures in the past months in the Netherlands, the Company decided to hold the AGM in physical form
in the Netherlands with the following organisational measures:
|
|
-
|
No social gatherings surrounding the AGM will take place.
|
|
|
-
|
To be able to safeguard 1.5 meters distance between all attendees, the Company encourages shareholders
and other persons with meeting rights, including proxy holders, not to attend the AGM but to exercise their voting rights by written or
electronic proxy in accordance with the procedure described below.
|
|
|
-
|
Shareholders and other persons with meeting rights, including proxy holders, who, despite current circumstances
and associated health risks, wish to attend the meeting in person must come alone and, in addition to the below registration process,
provide a valid e-mail address and telephone number to the Company by e-mail to investorrelations@immatics.com. These contact details
will be used to inform the registered attendees of any last-minute changes or requirements.
|
|
|
-
|
All attendees will be requested to wash and disinfect their hands before entry of the meeting room. Persons
showing symptoms of COVID-19 are strongly advised to stay home and will not be admitted in the meeting.
|
|
|
-
|
On behalf of the Company only the CEO, CFO, General Counsel and the Chairman of the Supervisory Board
will physically attend. The new candidate nominated for appointment as supervisory director and the candidates nominated for reappointment
as supervisory director may not be able to attend due to international restrictions or negative travel advice. The CEO, CFO and the General
Counsel will not be available for social interaction other than during the AGM itself.
|
|
|
-
|
The Company keeps continuous track of the developments with respect to the COVID-19 pandemic, including
information and guidance published by healthcare authorities. If, in the opinion of the Company or by governmental directive, a health
or safety issue would arise in relation to the meeting, last-minute changes to logistics or venue including additional requirements or
limitations in relation to the attendance in person, may be taken. The Company
|
will inform
persons with meeting rights of any such changes. You are advised to regularly check the Company's website for any updated information
on the AGM.
Record date
The Record Date for the AGM is 20 May 2021, which
is the 28th day prior to the date of the AGM. Each share outstanding on the Record Date entitles the holder to one vote on
each voting item at the AGM.
Shareholders of Record and Beneficial Owners
Shareholders of Record are those who are shareholders
of the Company, or otherwise have voting rights or meeting rights in respect of shares in the Company's share capital, at the Record Date
and who are recorded as such in the Company's register of shareholders.
Beneficial Owners are those who beneficially own
shares in the Company's share capital through a bank, broker or other nominee on the Record Date.
Attendance
A Shareholder of Record who wishes to attend
the AGM, in person or by a proxy, must notify the Company of its intention to do so by e mail at investorrelations@immatics.com no later
than 18.00 hours CET on 11 June 2021. The notice must contain the name and the number of shares the Shareholder of Record will represent
at the AGM. In addition, a Shareholder of Record who wishes to attend the AGM by a proxy must enclose its signed proxy. A proxy can be
downloaded from the Company's website at https://investors.immatics.com/events/event-details/annual-general-meeting-0.
A Beneficial Owner who wishes to attend the AGM
in person must notify the Company of its intention to do so by e-mail at investorrelations@immatics.com no later than 18.00 hours CET
on 11 June 2021. The notice must contain the name and the number of shares the Beneficial Owner will represent at the AGM. In addition,
the Beneficial Owner must enclose:
|
|
(a)
|
proof of its beneficial ownership of the relevant shares, for instance a recent account statement;
|
|
|
(b)
|
a signed proxy from the bank, broker or other nominee registered in the Company's register of shareholders
as the holder of the relevant shares on the Record Date confirming that the Beneficial Owner is authorised to attend the AGM. Beneficial
Owners should contact their bank, broker or other nominee to obtain this proxy from them; and
|
|
|
(c)
|
if the Beneficial Owner wishes to attend
the AGM by a proxy, a signed proxy. A proxy can be downloaded from the Company's website
at https://investors.immatics.com/events/event-details/annual-general-meeting-0.
|
Any notice of attendance, proof of beneficial
ownership or signed proxy received after 18.00 hours CET on 11 June 2021 will be disregarded. Shareholders of Record, Beneficial Owners
and proxyholders who have not complied with the procedures described above may be refused entry to the AGM.
All attendees must be prepared to show a valid
proof of identity for admittance.
How to vote
Shareholders of Record may vote in person or by
proxy at the AGM in accordance with the procedures described above.
Beneficial Owners may vote in person or by proxy
at the AGM in accordance with the procedures described above or have their shares voted by following the procedures specified on their
broker's voting
instruction form. Shortly before the AGM, the
brokers will tabulate the votes they have received and submit one or more proxy cards to the Company reflecting the aggregate votes of
the Beneficial Owners.
Contact details
For further information please
contact the Company's Investor Relations Department by e-mail at investorrelations@immatics.com.
Exhibit 99.3
AGENDA of the ANNUAL
GENERAL MEETING OF immatics N.V.
Agenda of the annual general
meeting of Immatics N.V., a public company under Dutch law, registered with the Dutch trade register under number 77595726 (the "Company"),
to be held at the offices of CMS, Atrium, Parnassusweg 737, 1077 DG Amsterdam, the Netherlands, on 17 June 2021 at 14.00 hours CET (the
"AGM").
|
1.
|
Opening
|
|
|
|
|
|
|
|
|
2.
|
Consideration of the the management report regarding the financial year ended 31 December 2020
|
|
Discussion item
|
|
|
|
|
|
|
3.
|
Adoption of the annual accounts for the financial year ended 31 December 2020
|
|
Voting item
|
|
|
|
|
|
|
4.
|
Discharge of the managing directors for their management during the financial year ended 31 December 2020
|
|
Voting item
|
|
|
|
|
|
|
5.
|
Discharge of the supervisory directors for their supervision during the financial year ended 31 December 2020
|
|
Voting item
|
|
|
|
|
|
|
6.
|
Appointment of Dr. E.R. Forster as supervisory director class I and appointment of Dr. E.R. Forster as non-executive director class I
|
|
Voting item
|
|
|
|
|
|
|
7.
|
Appointment of Dr. F.H. von Bohlen und Halbach as supervisory director class III and appointment of Dr. F.H. von Bohlen und Halbach as non-executive director class III
|
|
Voting item
|
|
|
|
|
|
|
8.
|
Reappointment of Mr. P.R. Carter as supervisory director class I and appointment of Mr. P.R. Carter as non-executive director class I
|
|
Voting item
|
|
|
|
|
|
|
9.
|
Reappointment of Mr. M.G. Atieh as supervisory director class I and appointment of Mr. M.G. Atieh as non-executive director class I
|
|
Voting item
|
|
|
|
|
|
|
10.
|
Extension of the authorisation of the Management Board to acquire ordinary shares or depositary receipts thereof
|
|
Voting item
|
|
|
|
|
|
|
11.
|
Extension of the authorisation of the Management Board to acquire preferred shares or depositary receipts thereof
|
|
Voting item
|
|
|
|
|
|
|
12.
|
Assignment of PricewaterhouseCoopers Accountants N.V. as auditor for the financial year 2021
|
|
Voting item
|
|
|
|
|
|
|
13.
|
Other matters for discussion
|
|
|
|
|
|
|
|
|
14.
|
Close
|
|
|
|
|
|
|
|
EXPLANATORY NOTES
TO THE AGENDA of the ANNUAL GENERAL MEETING OF immatics N.V.
|
|
2.
|
Consideration of the management report regarding the financial year ended 31 December 2020
|
Consideration of
the statutory management report for the financial year ended 31 December 2020 as prepared in accordance with Dutch law. The statutory
management report is available on the Company's website at https://investors.immatics.com/events-presentations and is available for inspection
at the offices of the Company.
|
|
3.
|
Adoption of the annual accounts for the financial year ended 31 December 2020
|
It is proposed that
the statutory annual accounts for the financial year ended 31 December 2020 as prepared in accordance with Dutch law and International
Financial Reporting Standards (IFRS) be adopted. The adoption of the statutory annual accounts includes the allocation of the losses made
in the financial year ended 31 December 2020. PwC has audited the the statutory annual accounts and issued an auditor's report in respect
thereof. The statutory annual accounts are available on the Company's website at https://investors.immatics.com/events-presentations and
are available for inspection at the offices of the Company.
|
|
4.
|
Discharge of the managing directors for their management during the financial year ended 31 December
2020
|
It is proposed that
each managing director in office during the financial year ended 31 December 2020 be granted a discharge from liability for the exercise
of his management duties during the financial year ended 31 December 2020 to the extent appearing from the statutory annual accounts or
the statutory management report for the financial year ended 31 December 2020 or other public disclosures.
|
|
5.
|
Discharge of the supervisory directors for their supervision during the financial year ended 31 December
2020
|
It is proposed that
each supervisory director in office during the financial year ended 31 December 2020 be granted a discharge from liability for the exercise
of his supervisory duties during the financial year ended 31 December 2020 to the extent appearing from the statutory annual accounts
or the report of the Superviusory Board for the financial year ended 31 December 2020 or other public disclosures.
|
|
6.
|
Appointment of Dr. E.R. Forster as supervisory director class I and appointment of Dr. E.R.
Forster as non-executive director class I
|
In accordance with
the applicable provisions of the Articles of Association, the Supervisory Board has nominated Dr. E.R. Forster for appointment as
supervisory director class I effective as of the date of the AGM and appointment as non-executive director class I effective
as of 1 July 2021. Dr. Forster has served as an interim member of the Supervisory Board since September 2020.
Eliot Forster Ph.D.
was born on 27 February 1966. Dr. Forster has served on the Supervisory Board since September 2020. Since 2018, Dr. Forster has served
as the Chief Executive Officer of F-star Therapeutics Ltd. From 2015 to 2018, Dr. Forster served as the Chief Executive Officer of Immunocore
Limited. Prior to that, Dr. Forster served as the Chief Executive Officer of Creabilis SA, as the Chief Executive Officer of Solace Pharmaceuticals
Inc., as Head of Development and Operations for the EU and Asia at Pfizer Inc. Dr. Forster is an honorary visiting Professor of Molecular
and Clinical Cancer Medicine at the University of Liverpool and an honorary international visiting Professor at the University of Pavia.
Dr. Forster serves on the board of directors of F-star Therapeutics Ltd, Avacta Group plc and OSCHR (Office for Strategic Coordination
of Health Research) and the National Genomics Board and has previously served on the board of directors of MedCity Ltd., Spinifex Pty
Ltd, Oxford BioTherapeutics and Atlantic Healthcare (UK) Ltd. Dr. Forster holds a B.Sc. in physiology from the Unversity of Liverpool,
an M.B.A. from Henley Business School and a Ph.D. in neurophysiology from the University of Liverpool.
Dr. Forster does
not hold any shares in the share capital of the Company.
Given Dr. Forster's
extensive experience, the Supervisory Board is of the opinion that the Company will benefit from Dr. Forster's membership on the Supervisory
Board and, after the conversion of the Company's two-tier board structure into a one tier board, the Board.
It is proposed that
Dr. E.R. Forster be appointed as supervisory director class I effective as of the date of the AGM and be appointed as non-executive
director class I effective as of 1 July 2021. The proposed appointment is for a continuous term ending at the close of the annual
general meeting to be held in 2024.
Dr. E.R. Forster's
Services Agreement provides that it will automatically terminate upon the expiry of the term of his appointment. The remuneration of Dr. E.R.
Forster has been determined in line with the remuneration policy as applicable to the supervisory directors of the Company.
Below is an overview
of the remuneration for Dr. E.R. Forster as included in his Services Agreement:
|
|
-
|
fixed annual remuneration: EUR 40,000 gross; and
|
|
|
-
|
stock options and incentives: 25,000 stock options.
|
The appointment of Mr. E.R. Forster
as supervisory director class I includes the determination of the remuneration set out above.
When making the nomination of Dr. E.R.
Forster for appointment as supervisory director class I, the Supervisory Board took into account the profile of the Supervisory Board
and the applicable independence standards of the Stock Market Rules of the Nasdaq Stock Market LLC. Dr. E.R. Forster is considered
independent under Rule 5605(a)(2) under the Stock Market Rules of the Nasdaq Stock Market LLC.
|
|
7.
|
Appointment of Dr. F.H. von Bohlen und Halbach as supervisory director class III and appointment
of Dr. F.H. von Bohlen und Halbach as non-executive director class III
|
In accordance with the applicable provisions
of the Articles of Association, the Supervisory Board has nominated Dr. F.H. von Bohlen und Halbach for appointment as supervisory
director class III effective as
of the date of the AGM and appointment as non-executive director class III effective as of 1 July 2021.
The Supervisory Board has nominated
Dr. F.H. von Bohlen und Halbach for appointment as supervisory director class III and appointment as non-executive director class III
at the request of dievini Hopp BioTech holding GmbH & Co. KG in accordance with the applicable provisions of the investor rights and
lock up agreement dated 17 March 2020 between the Company, dievini Hopp BioTech holding GmbH & Co. KG and the other investors named
therein, which agreement was entered into in connection with the business combination agreement dated 17 March 2020 between the Company,
Immatics Biotechnologies GmbH, ARYA Sciences Acquisition Corp., Immatics Merger Sub 1 and Immatics Merger Sub 2, as amended on 7 June
2020. Dr. F.H. von Bohlen und Halbach will replace Mr. C.A. Hettich, who has been appointed supervisory director on the basis of
the nomination rights of dievini Hopp BioTech holding GmbH & Co. KG under the said investor rights and lock up agreement and who has
recently announced to resign on or prior to the date of the AGM.
Dr. Friedrich von Bohlen und Halbach
is managing partner and co-founder of dievini Hopp BioTech Holding GmbH & Co. KG., the company managing the life science activities
and investments of Dietmar Hopp, co-founder of SAP, and his family.
Friedrich von Bohlen holds a diploma
in biochemistry from the University of Zurich and a PhD in neurobiology from the Swiss Federal Institute of Technology (ETH) in Zurich.
He held various positions at Fresenius
AG, FAG Kugelfischer KGaA and WASAG Chemie AG. In 1997 he founded LION bioscience AG whose CEO he was for seven years. He is chairman
of the Board of Apogenix AG and Novaliq GmbH, and board member of CureVac AG, Heidelberg Pharma AG and Co-Chair of the Evaluation Board
of the Wyss Translational Center Zurich. Friedrich von Bohlen is also co-founder and managing director of Molecular Health GmbH.
Dr. von Bohlen und Halbach does not
hold any shares in the share capital of the Company.
Given Dr. von Bohlen und Halbach's
extensive business leadership experience, the Supervisory Board is of the opinion that the Company will benefit from Dr. von Bohlen und
Halbach's membership on the Supervisory Board and, after the conversion of the Company's two-tier board structure into a one tier board,
the Board.
It is proposed that Dr. F.H. von Bohlen
und Halbach be appointed as supervisory director class III effective as of the date of the AGM and be appointed as non-executive
director class III effective as of 1 July 2021. The proposed appointment is for a continuous term ending at the close of the annual
general meeting to be held in 2023.
Below is an overview
of the remuneration for Dr. F.H. von Bohlen und Halbach as included in his Services Agreement:
|
|
-
|
fixed annual remuneration: EUR 40,000 gross; and
|
|
|
-
|
stock options and incentives: 25,000 stock options.
|
The appointment of Dr. F.H. von Bohlen
und Halbach as supervisory director class III includes the determination of the remuneration set out above.
When making the nomination of Dr. F.H.
von Bohlen und Halbach for appointment as supervisory director class III, the Supervisory Board took into account the profile of
the Supervisory Board and the applicable independence standards of the Stock Market Rules of the Nasdaq Stock Market LLC. Dr. F.H. von
Bohlen und Halbach is considered independent under Rule 5605(a)(2) under the Stock Market Rules of the Nasdaq Stock Market.
|
|
8.
|
Reappointment of Mr. P.R. Carter as supervisory director class I and appointment of Mr. P.R. Carter
as non-executive director class I
|
In accordance with
the applicable provisions of the Articles of Association, the Supervisory Board has nominated Mr. P.R. Carter for reappointment as supervisory
director class I effective as of the date of the AGM and appointment as non-executive director class I effective as of 1 July
2021.
Paul R. Carter FCMA
was born on 13 July 1960. Mr. Carter has served on the Supervisory Board since 2020. From 2014 to 2016, Mr. Carter served as Executive
Vice President, Commercial Operations of Gilead Sciences, Inc. Prior to that, Mr. Carter served as Senior Vice President and Head, International
Commercial Operations of Gilead Sciences, Inc. and in various senior positions over a 10-year period at GlaxoSmithKline plc, including
as Regional Vice President, China & Hong Kong, Vice President and General Manager, Pharmaceutical & Consumer Health, Hong Kong
& South China, and General Manager, SmithKline Beecham Consumer Health, Russia & CIS. In addition to the Supervisory Board, Mr.
Carter serves on the board of directors of Evox Therapeutics Ltd, Mallinckrodt PLC and Hutchison China MediTech Ltd. and has previously
served on the board of directors of Alder Biopharmaceuticals Inc. Mr. Carter also serves as an advisor to Astorg Partners SAS, ZambonGroup,
Indegene Inc. and GLG Institute. Mr. Carter holds a B.A. in business studies from the University of West London.
Mr. Carter does
not hold any shares in the share capital of the Company.
Mr. Carter joined
the Supervisory Board in July 2020 and serves as chairman of the compensation committee and is a member of the audit committee. Given
Mr. Carter's extensive business leadership experience within the life sciences industry and valuable contribution to the Company, the
Supervisory Board is of the opinion that the Company will continue to benefit from Mr. Carter's membership on the Supervisory Board and,
after the conversion of the Company's two-tier board structure into a one tier board, the board.
It is proposed that
Mr. P.R. Carter be reappointed as supervisory director class I effective as of the date of the AGM and be appointed as non-executive
director class I effective as of 1 July 2021. The proposed reappointment and appointment are for a continuous term ending at the
close of the annual general meeting to be held in 2024.
Mr. P.R. Carter's
Services Agreement provides that it will automatically terminate upon the expiry of the term of his appointment. The remuneration of Mr. P.R.
Carter has been determined in line with the remuneration policy as applicable to the supervisory directors of the Company.
Below is an overview
of the remuneration for Mr. P.R. Carter as included in his Services Agreement:
|
|
-
|
fixed annual remuneration: EUR 52,500 gross; and
|
|
|
-
|
stock options and incentives: 25,000 stock options.
|
The reappointment
of Mr. P.R. Carter as supervisory director class I includes the determination of the remuneration set out above.
When making the nomination of Mr. P.R.
Carter for reappointment as supervisory director class I, the Supervisory Board took into account the profile of the Supervisory
Board and the applicable independence standards of the Stock Market Rules of the Nasdaq Stock Market LLC. Mr. P.R. Carter is considered
independent under Rule 5605(a)(2) under the Stock Market Rules of the Nasdaq Stock Market LLC.
|
|
9.
|
Reappointment of Mr. M.G. Atieh as supervisory director class I and appointment of Mr. M.G.
Atieh as non-executive director class I
|
In accordance with
the applicable provisions of the Articles of Association, the Supervisory Board has nominated Mr. M.G. Atieh for reappointment as
supervisory director class I effective as of the date of the AGM and appointment as non-executive director class I effective
as of 1 July 2021.
Michael G. Atieh
was born on 8 August 1953. Mr. Atieh has served on the Supervisory Board since 2020. From 2014 until his retirement in 2016, Mr. Atieh
served as Executive Vice President, Chief Financial and Business Officer of Ophthotech Inc. Prior to that, he served as Executive Chairman
of Eyetech Inc., as Executive Vice President and Chief Financial Officer of OSI Pharmaceuticals, as Group President – Global Business
Unit and as Senior Vice President and Chief Financial Officer of Cegedim Inc., and in various executive-level positions over a 19-year
period at Merck and Co., Inc., including as Vice President – U.S. Human Health, Senior Vice President – Merck Medco Managed
Care, Vice President – Public Affairs, Vice President – Government Relations, and Treasurer. In addition to the Supervisory
Board, Mr. Atieh serves on the board of directors of Chubb Limited, electroCore, Inc. and Oyster Point Pharma, Inc. and has previously
served on the board of directors of Theravance BioPharma, Eyetech Inc. and OSI Pharmaceuticals. Mr. Atieh holds a B.A. in accounting from
Upsala College.
Mr. Atieh does not
hold any shares in the share capital of the Company.
Mr. Atieh joined
Supervisory Board in July 2020 and serves as chairman of the audit committee. Given Mr. Atieh's business leadership experience, financial
background, track record within the life sciences industry, and valuable contribution to the Company, the Supervisory Board is of the
opinion that the Company will continue to benefit from Mr. Atieh's membership on the Supervisory Board and, after the conversion of the
Company's two-tier board structure into a one tier board, the board.
It is proposed that
Mr. M.G. Atieh be reappointed as supervisory director class I effective as of the date of the AGM and be appointed as non-executive
director class I effective as of 1 July 2021. The proposed reappointment and appointment are for a continuous term ending at the
close of the annual general meeting to be held in 2024.
Mr. M.G. Atieh's
Services Agreement provides that it will automatically terminate upon the expiry of the term of his appointment. The remuneration of Mr. M.G.
Atieh has been determined in line with the remuneration policy as applicable to the supervisory directors of the Company.
Below is an overview
of the remuneration for Mr. M.G. Atieh as included in his Services Agreement:
|
|
-
|
fixed annual remuneration: EUR 55,000 gross; and
|
|
|
-
|
stock options and incentives: 25,000 stock options.
|
The reappointment
of Mr. M.G. Atieh as supervisory director class I includes the determination of the remuneration set out above.
When making the nomination of Mr. M.G.
Atieh for appointment as supervisory director class I, the Supervisory Board took into account the profile of the Supervisory Board
and the applicable independence standards of the Stock Market Rules of the Nasdaq Stock Market LLC. Mr. M.G. Atieh is considered
independent under Rule 5605(a)(2) under the Stock Market Rules of the Nasdaq Stock Market LLC.
|
|
10.
|
Extension of the authorisation of the Management Board to acquire ordinary shares or depositary receipts
thereof
|
On 30 June 2020,
the general meeting of the Company authorised the Management Board to acquire ordinary shares in the share capital of the Company or depositary
receipts thereof for consideration for a period of eighteen months, commencing on 1 July 2020, therefore ending on 31 December 2021.
It is proposed that
the authorisation of the Management Board to acquire ordinary shares in the share capital of the Company or depositary receipts thereof
for consideration be extended for a period of eighteen months, commencing on 17 June 2021.
The maximum number
of ordinary shares permitted pursuant to applicable law and the articles of association from time to time may be acquired and ordinary
shares may be acquired through repurchases negotiated in the open market or privately, in self-tender offers, or through accelerated repurchase
arrangements, at prices ranging from the nominal value of the ordinary shares up to 110% of the market price of ordinary shares, provided
that:
|
|
(a)
|
for open market or privately negotiated repurchases, the market price shall be the price for ordinary
shares on the Nasdaq Stock Market at the time of the transaction;
|
|
|
(b)
|
for self-tender offers, the market price shall be the volume weighted average price for the ordinary shares
on the Nasdaq Stock Market during a period, determined by the Management Board, of no less than one and no more than five consecutive
trading days immediately prior to the expiration of the tender offer; and
|
|
|
(c)
|
for accelerated repurchase arrangements, the market price shall be the volume weighted average price of
the ordinary shares on the Nasdaq Stock Market over the term of the arrangement; the volume weighted average price for any number of trading
days shall be calculated as the arithmetic average of the daily volume weighted average price on those trading days;
|
The authorisation
referred to above, as extended, shall survive the transition of the Articles of Association in accordance with article 50 of the articles
of association and such authorisation, as extended, shall, to the extent necessary, from 1 July 2021 be deemed to have been granted to
the board of the Company for the unexpired period of the authorisation, as extended.
|
|
11.
|
Extension of the authorisation of the Management Board to acquire preferred shares or depositary receipts
thereof
|
On 30 June 2020,
the general meeting of the Company authorised the Management Board to acquire financing preferred shares in the share capital of the Company
or depositary receipts thereof for consideration for a period of eighteen months, commencing on 1 July 2020, therefore ending on 31 December
2021.
It is proposed that
the authorisation of the Management Board to acquire financing preferred shares in the share capital of the Company or depositary receipts
thereof for consideration for a period of eighteen months, commencing on 17 June 2021.
The maximum number
of financing preferred shares permitted pursuant to applicable law and the articles of association from time to time may be acquired and
financing preferred shares may be acquired through repurchases negotiated in the open market or privately, in self-tender offers, or through
accelerated repurchase arrangements, at prices ranging from the nominal value of the financing preferred shares up to the higher of:
|
|
(a)
|
the amount that would be paid by the Company upon cancellation of such financing preferred shares in accordance
with the relevant provisions of the Articles of Association; and
|
|
|
(b)
|
110% of the market price of the ordinary shares into which the financing preferred shares may be converted
in accordance with the relevant provisions of the Articles of Association, whereby the market price will be determined in the manner as
set out above under paragraph (a).
|
The authorisation
referred to above, as extended, shall survive the transition of the Articles of Association in accordance with article 50 of the articles
of association and such authorisation, as extended, shall, to the extent necessary, from 1 July 2021 be deemed to have been granted to
the board of the Company for the unexpired period of the authorisation, as extended.
|
|
12.
|
Assignment of PricewaterhouseCoopers Accountants N.V. as auditor for the financial year 2021
|
PricewaterhouseCoopers
Accountants N.V. has audited the Company's statutory annual accounts for the financial year ended 31 December 2020.
It is proposed that
PricewaterhouseCoopers Accountants N.V. be assigned as auditor to audit the Company's statutory annual accounts for the financial year
2021.
|
|
13.
|
Other matters for discussion
|
